SkelRegen is the first company to identify multiple osteoinductive small molecule families that leverage repurposed drugs and novel chemical entities; are delivered on a collagen sponge to the defect area; and allow the safe regeneration of musculoskeletal tissues from scratch.These compounds are extremely inexpensive to manufacture giving tremendous pricing flexibility, and two molecule families have already been cleared by FDA for other uses, which means they already have acceptable safety and toxicity profiles.